BALTIMORE, March 26, 2015 /PRNewswire/ — Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a research report on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. The report carries a rating and a price target. To view the sponsored research report, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech is an innovative biotechnology company whose therapeutic technology platform could emerge as the go-to treatment of choice for different types of cancers and diabetes representing billions of dollars in market opportunity. Plus, the Company is engaged in the study of cannabinoids (constituents of the Cannabis plant) in combination with its flagship Cell-in-a-Box® technology as treatments for deadly cancers such as brain cancer.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis:
“In our view, PharmaCyte Biotech sits in an enviable position, with multiple shots on goal as a potential universal therapy for the treatment of multiple forms of cancer and diabetes. The Company’s flagship technology, Cell-in-a-Box®, has recently been granted Orphan Drug Status by the FDA for the treatment of advanced, inoperable pancreatic cancer when used in combination with the chemotherapy drug ifosfamide at one-third the dose normally given. This designation serves as a major boost to the Company’s development efforts, its standing as a key player in the pancreatic cancer treatment arena and validates the Cell-in-a-Box® technology.”
“Moreover, PharmaCyte Biotech has achieved enviable developmental progress over the past year and the launch of a series of clinical trials in 2015 should raise the Company’s profile. These milestones include mid-stage and preclinical studies for the treatment of pancreatic cancer and its serious and debilitating symptoms, and for diabetes. Based on our pancreatic treatment peer group analysis alone, PharmaCyte Biotech’s progress and industry status appear grossly overlooked. Considering the potential technology portability into the treatment of diabetes, a disease affecting millions with no cure, and other forms of cancer, the future potential reach of the technology may be greater than that of typical mid-stage biotechs.”
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research has been compensated by a third party in the amount of $4000 for investment research services.
About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB – PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.
Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]
SOURCE Goldman Small Cap Research
